Company Profile
Vor Biopharma Stock Price, News & Catalysts
- Ticker:
- VOR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
23.36 USD (+1.28%)
Close
Last updated: August 21, 2026
740M USD
Market cap
Why the stock is moving
As of Aug 21, 2026, VOR closed up 1.28% at $23.36. No new same-company headline was identified in the current news window.
Company overview
Autoimmune B-Cell Therapy Company
Vor Bio is developing telitacicept for antibody-driven autoimmune diseases.
Telitacicept
Telitacicept is a recombinant fusion protein that inhibits both BAFF and APRIL, reducing survival signals for autoreactive B cells and plasma cells.
Global Phase 3 Programs
The UPSTREAM program is evaluating telitacicept in generalized myasthenia gravis and primary Sjögren’s disease.
Future catalysts
- Topline results from the Phase 3 UPSTREAM MG study are anticipated in the first half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Vor Biopharma (VOR)?
Vor Biopharma (VOR) most recently closed at 23.36 USD, a +1.28% move versus the previous session.
What is the market cap of Vor Biopharma (VOR)?
Vor Biopharma currently has a market capitalization of 740M USD on BioPharmSignal.
What does Vor Biopharma do?
Autoimmune B-Cell Therapy Company Vor Bio is developing telitacicept for antibody-driven autoimmune diseases. Telitacicept Telitacicept is a recombinant fusion protein that inhibits both BAFF and APRIL, reducing survival signals for autoreactive B cells and plasma cells. Global Phase 3 Programs The UPSTREAM program is evaluating telitacicept in generalized...
On which exchange is VOR stock listed?
Vor Biopharma (VOR) is associated with NASDAQ, United States, Biopharma.
What is telitacicept?
Autoimmune B-Cell Therapy Company Vor Bio is developing telitacicept for antibody-driven autoimmune diseases.
Which conditions is Vor Biopharma targeting with telitacicept?
Autoimmune B-Cell Therapy Company Vor Bio is developing telitacicept for antibody-driven autoimmune diseases. Telitacicept Telitacicept is a recombinant fusion protein that inhibits both BAFF and APRIL, reducing survival signals for autoreactive B cells and plasma cells. Global Phase 3 Programs The UPSTREAM program is evaluating telitacicept in generalized...
How does Vor Biopharma describe recent progress with telitacicept?
Topline results from the Phase 3 UPSTREAM MG study are anticipated in the first half of 2027.
What is Autoimmune?
Autoimmune B-Cell Therapy Company Vor Bio is developing telitacicept for antibody-driven autoimmune diseases.